📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. (2019)

First Author: Betts CA

Attributed to: Peptide conjugated oligonucleotides for a phase I/IIa clinical trial in Spinal Muscular Atrophy funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/hmg/ddy346

PubMed Identifier: 30281092

Publication URI: http://europepmc.org/abstract/MED/30281092

Type: Journal Article/Review

Volume: 28

Parent Publication: Human molecular genetics

Issue: 3

ISSN: 0964-6906